These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 19270263)

  • 1. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy.
    Pérez-Andreu V; Roldán V; Antón AI; García-Barberá N; Corral J; Vicente V; González-Conejero R
    Blood; 2009 May; 113(20):4977-9. PubMed ID: 19270263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of acenocoumarol in patients with extreme dose requirements.
    Pérez-Andreu V; Roldán V; López-Fernández MF; Antón AI; Alberca I; Corral J; Montes R; García-Barberá N; Ferrando F; Vicente V; González-Conejero R
    J Thromb Haemost; 2010 May; 8(5):1012-7. PubMed ID: 20149073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Creating a genotype-based dosing algorithm for acenocoumarol steady dose.
    Cerezo-Manchado JJ; Rosafalco M; Antón AI; Pérez-Andreu V; Garcia-Barberá N; Martinez AB; Corral J; Vicente V; González-Conejero R; Roldán V
    Thromb Haemost; 2013 Jan; 109(1):146-53. PubMed ID: 23196355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: a potential role of CYP4F2 and GGCX polymorphisms.
    Wypasek E; Branicka A; Awsiuk M; Sadowski J; Undas A
    Thromb Res; 2014 Sep; 134(3):604-9. PubMed ID: 25042728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patients.
    Smires FZ; Moreau C; Habbal R; Siguret V; Fadili S; Golmard JL; Assaidi A; Beaune P; Loriot MA; Nadifi S
    J Clin Pharm Ther; 2012 Oct; 37(5):594-8. PubMed ID: 22486182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotype-guided therapy improves initial acenocoumarol dosing. Results from a prospective randomised study.
    Cerezo-Manchado JJ; Roldán V; Corral J; Rosafalco M; Antón AI; Padilla J; Vicente V; González-Conejero R
    Thromb Haemost; 2016 Jan; 115(1):117-25. PubMed ID: 26538428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of CYP4F2, CYP2C19, and CYP1A2 polymorphisms on acenocoumarol pharmacogenomic algorithm accuracy improvement in the Greek population: need for sub-phenotype analysis.
    Ragia G; Karantza IM; Kelli-Kota E; Kolovou V; Kolovou G; Konstantinides S; Maltezos E; Tavridou A; Tziakas D; Maitland-van der Zee AH; Manolopoulos VG
    Drug Metab Pers Ther; 2017 Dec; 32(4):183-190. PubMed ID: 29252193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment.
    Cerezo-Manchado JJ; Roldan V; Rosafalco M; Anton AI; Arroyo AB; Garcia-Barbera N; Martínez AB; Padilla J; Corral J; Vicente V; Gonzalez-Conejero R
    Pharmacogenomics; 2014 May; 15(7):987-96. PubMed ID: 24956252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant.
    McDonald MG; Rieder MJ; Nakano M; Hsia CK; Rettie AE
    Mol Pharmacol; 2009 Jun; 75(6):1337-46. PubMed ID: 19297519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of genetic and non-genetic factors on acenocoumarol maintenance dose requirement in a Tunisian population.
    Ajmi M; Omezzine A; Achour S; Amor D; Hamdouni H; Ismaïl FBF; Rejeb NB; Kechrid CL; Boughzela E; Bouslama A
    Eur J Clin Pharmacol; 2018 Jun; 74(6):711-722. PubMed ID: 29479633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes.
    Teichert M; Eijgelsheim M; Uitterlinden AG; Buhre PN; Hofman A; De Smet PA; Visser LE; Stricker BH
    Pharmacogenet Genomics; 2011 Jan; 21(1):26-34. PubMed ID: 21063236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.
    Bodin L; Verstuyft C; Tregouet DA; Robert A; Dubert L; Funck-Brentano C; Jaillon P; Beaune P; Laurent-Puig P; Becquemont L; Loriot MA
    Blood; 2005 Jul; 106(1):135-40. PubMed ID: 15790782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of CYP2C9, VKORC1, CYP4F2, and GGCX gene variants and patient characteristics on acenocoumarol maintenance dose: Proposal for a dosing algorithm for Moroccan patients.
    Elkhazraji A; Bouaiti EA; Boulahyaoui H; Nahmtchougli CP; Zahid H; Bensaid M; Ibrahimi A; Messaoudi N
    Drug Discov Ther; 2018; 12(2):68-76. PubMed ID: 29760340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.
    Daly AK
    Arch Toxicol; 2013 Mar; 87(3):407-20. PubMed ID: 23376975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
    Beinema M; Brouwers JR; Schalekamp T; Wilffert B
    Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data.
    van Schie RM; Wessels JA; le Cessie S; de Boer A; Schalekamp T; van der Meer FJ; Verhoef TI; van Meegen E; Rosendaal FR; Maitland-van der Zee AH;
    Eur Heart J; 2011 Aug; 32(15):1909-17. PubMed ID: 21636598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics role in the safety of acenocoumarol therapy.
    Jiménez-Varo E; Cañadas-Garre M; Henriques CI; Pinheiro AM; Gutiérrez-Pimentel MJ; Calleja-Hernández MÁ
    Thromb Haemost; 2014 Sep; 112(3):522-36. PubMed ID: 24919870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients.
    Montes R; Ruiz de Gaona E; Martínez-González MA; Alberca I; Hermida J
    Br J Haematol; 2006 Apr; 133(2):183-7. PubMed ID: 16611310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An acenocoumarol dosing algorithm exploiting clinical and genetic factors in South Indian (Dravidian) population.
    Krishna Kumar D; Shewade DG; Loriot MA; Beaune P; Sai Chandran BV; Balachander J; Adithan C
    Eur J Clin Pharmacol; 2015 Feb; 71(2):173-81. PubMed ID: 25519826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The c.-1639g > A polymorphism of the VKORC1 gene and his influence on the therapeutic response during oral anticoagulants use].
    Kovac M; Rakićević L; Maslać A; Radojković D
    Vojnosanit Pregl; 2009 Aug; 66(8):617-21. PubMed ID: 19780415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.